KRAS G12D
A KRAS change commonly found in pancreatic and colorectal cancer, with treatment options still limited.
Parent marker: KRAS
Not a diagnosis and not final medical advice. Must be reviewed by a doctor.
Clinical meaning
G12D does not yet have a widely approved inhibitor. These changes are primarily discussed within the framework of clinical trials and research.
How this finding appears in a report
Found via sequencing panel; specific variants need to be reported.
When therapy stops working
Subsequent discussions depend on the availability of ongoing studies.
What needs verification
- Complete variant name as written in the laboratory report.
- Examination methods and types of samples used.
- Examination dates were compared with ongoing therapy.
Marker context: KRAS
KRAS G12C alterations have specific inhibitor options, while other alterations are generally directed to standard pathways or clinical trials. KRAS mutations often appear together with other markers such as STK11 or KEAP1, which can also influence the discussion.
A negative result does not always mean absent
Summary
- Gen
- KRAS
- Variant
- KRAS G12D
- Alteration type
- Mutation
- Discussed in
- Pancreatic Cancer, Colorectal Cancer, Lung Cancer
- Updated
- 2026-09-10
Other names in reports
G12D
Treatment categories
Related guides
Sources
- NCI Dictionary of Cancer Terms(lembaga)
- ClinicalTrials.gov(registry)
Clinical trials
Studies mentioning marker KRAS
Filtered from public study descriptions. Access status and site readiness remain unverified.
NCT07020221Phase 1 / Phase 2Combination regimen
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Lung Cancer | biomarker: KRAS | Immunotherapy, Targeted therapy, Chemotherapy
United States, Australia15 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07020221Not verified
NCT07458347Phase 1Immunotherapy
A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Lung Cancer | biomarker: KRAS | Immunotherapy, Chemotherapy
United States9 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07458347Not verified
NCT07468071Phase 1 / Phase 2Targeted therapy
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Lung Cancer | biomarker: KRAS | Targeted therapy
Belgium, Canada, China +720 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Active, not recruiting
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07468071Not verified
NCT07659782Phase 2Targeted therapy
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Lung Cancer | biomarker: KRAS | Targeted therapy
United States, Australia, Puerto Rico22 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07659782Not verified
Next steps
These suggestions come from links between entries in TanyaKanker's database, not from a medical judgement. Each suggestion includes why it appears.
Next to learn
- KRAS
Biomarker
Reason: Related through a biomarker
- Colorectal Cancer
Cancer type
Reason: Related to this page
- Pancreatic Cancer
Cancer type
Reason: Related to this page
- Targeted therapy
Treatment category
Reason: Related to this page
- Lung Cancer
Cancer type
Reason: Related to this page
To check
- Check medical report completeness
Tool
Reason: Prepare documents that still need confirmation
- Prepare questions for your doctor
Tool
Reason: Bring clear questions to the next conversation
What you can do
- Upload medical reports
Build a case summary in twelve steps
Reason: Often the most useful next step after reading this page
- Request a second opinion
Review of the treatment plan
Reason: Relevant when a treatment plan is being considered
- Consult a navigator
A request is recorded with this page context
Reason: For asking the next step directly
Recently updated
- Leukemia
Cancer page
Date: Data revision 2026-09-10
- Brain Cancer
Cancer page
Date: Data revision 2026-09-10
- Pancreatic Cancer
Cancer page
Date: Data revision 2026-09-10
- Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149 - Phase 2
Date: Registry update in the last 30 days (2026-10-15)
Want to follow changes on this topic? Save the page or follow the topic so it is easy to find again. View saved items.
Prepare for your next consultation
Use the free six-question tool to prepare questions for your doctor.